top of page

THE FASTER WE MOVE

Join our presence at SABCS 2023

Updated: Nov 23, 2023

It’s almost the end of the year, which means it’s time for one of our favorite meetings The San Antonio Breast Cancer Symposium. This meeting brings together basic scientists and clinicians from across the globe to foster interactions and conversations that can lead to the improvement of diagnosis and treatment of breast cancer.

SABCS23 MEDSIR

This year we are thrilled to be participating onsite and we will be sharing five of our studies. We can’t wait to see you all there!


RF01-03 PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study.


The standard of care for HR+/HER2- advanced breast cancer is a combination of cyclin dependent kinase 4/6 (CDK4/6) inhibitors with hormone therapy. However, more information on the best combination and the long-term efficacy is needed. PARSIFAL was a phase II clinical trial that aimed to determine whether fulvestrant or letrozole was the optimal partner for palbociclib in the first-line setting in patients with endocrine-sensitive, HR+/HER2- advanced breast cancer. Previously, the trial determined that there was no difference between the two drugs in terms of progression-free survival at a median follow up of 2.7 years. At SABCS 2023, Dr. Antonio Llombart-Cussac will be sharing the extended analysis of the PARSIFAL trial with the efficacy results with a median follow up time of 5 years during a Rapid Fire Mini Oral Presentation. You won’t want to miss this important presentation.



Rapid Fire Session 1: Mini Oral Presentations

When: Wednesday, December 6th, 12:15PM-1PM

Where: Hall 1


PARSIFAL-LONG at SABCS23 MEDSIR


PS11-05 Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: Results from cohort 5 of the DEBBRAH study.


Leptomeningeal carcinomatosis is a rare but serious complication that happens when advanced cancer spreads to the cerebrospinal fluid and leptomeninges. There are no specific drugs approved for metastatic breast cancer patients with brain metastases and they are often excluded from clinical trials. The DEBBRAH clinical trial was designed to specifically address this and is investigating the efficacy and safety of trastuzumab deruxtecan in patients with both HER2-positive or HER2-low advanced breast cancer and a history of brain metastases or leptomeningeal carcinomatosis. The trial has five cohorts and during a Poster Spotlight Discussion, Dr. Marta Vaz will be sharing the overall survival results from cohort 5, which enrolled patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis. Make sure to stop by this exciting poster spotlight session.



Poster Spotlight Session – CNS Disease in Breast Cancer.

When: Thursday, December 7th, 7AM-8AM

Where: Hemisfair Ballroom 1-2


DEBBRAH Cohort 5 at SABCS23 MEDSIR

PS16-02 Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.


The ATRACTIB is a phase II clinical trial that focuses on triple-negative breast cancer (TNBC), characterized by the tumor lacking hormone receptors (both estrogen and progesterone) and the HER2 protein. TNBC accounts for 10 to 15% of all breast cancers and is associated with poor survival and few treatment options, compared to other types of breast cancer. The combination of immunotherapy using atezolizumab alongside paclitaxel chemotherapy has proven effective in advanced TNBC, especially in those patients with high expression of the PD-L1 protein. The ATRACTIB trial investigates the efficacy of the combination of first-line atezolizumab (immunotherapy), paclitaxel (chemotherapy) and bevacizumab (an antiangiogenic agent) in 100 patients with advanced TNBC regardless of their PDL1 status. Dr. María Gion will share the efficacy and safety results from this combination during the Spotlight Session on immunotherapy for TNBC. Make sure to add this interesting session to your calendar.




Poster Spotlight Session – Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and Biomarkers.

When: Friday, December 8th, 7AM-8AM

Where: Stars at Night Ballroom 3-4


ATRACTIB at SABCS23 MEDSIR


PO2-15-06 ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial.

In the framework of the PARSIFAL clinical trial, this retrospective study has evaluated the ability of DNADX (a novel machine learning tool employing genomic data) to predict prognosis and treatment benefit. This technology, developed by Reveal Genomics, analyzes genomic signatures encoded in circulating tumor DNA (ctDNA) and classifies patients according to them. Notably, these signatures have demonstrated to predict both survival rates and drug response in patients with metastatic breast cancer (Nature Communications). This exploratory study, involving MEDSIR and Reveal Genomics, is now evaluating DNADX's algorithm in HR+/HER2- advanced breast cancer patients from the PARSIFAL trial. The primary goal of the study is to assess whether ctDNA-based signatures correlate with the progression-free survival and overall survival of these patients, along with their predictive capacity for treatment response. Do not hesitate to stop by this poster for a deeper insight on the results and clinical potential of DNADX.



Poster Session 2

Poster Number: PO2-15-06

When: Wednesday, December 6th, 5PM-7PM

Where: Halls 2-3


PARSIFAL substudy at SABCS23 MEDSIR


PO1-20-02 MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC).


There is currently no test to determine which HR+/HER2- early breast cancer patients will relapse on standard of care treatment. Liquid biopsies based on circulating tumor DNA (ctDNA) offer a non-invasive alternative to traditional biopsies and have recently been used to detect minimal residual disease (MRD). MRD, or the small amount of tumor DNA that remains in the blood after treatment, may be able to early identify patients at risk of recurrence and those who might benefit from further treatment. The MiRaDor phase II clinical trial is a proof-of-concept study designed to test the usefulness of monitoring MRD using ctDNA in HR+/HER2- early breast cancer patients who are at high-risk for a relapse. The study will monitor ctDNA changes over time to correlate them with the risk of disease recurrence and to analyze the efficacy of escalating treatment for patients experiencing a relapse. Stop by the poster to learn about the design of this international clinical trial.


Poster Session 1

Poster Number: PO1-20-02

When: Wednesday, December 6th, 12PM-2PM

Where: Halls 2-3


MiRaDoR at SABCS23 MEDSIR


We’re excited to see you in San Antonio, connect with us to set up an appointment with a member of the team!


108 views

Comments


GET OUR MONTHLY NEWSLETTER!

bottom of page